VEG: collaboration for personalised epigenetic cancer therapy through pre-clinical evaluation, novel biomarker development and early phase clinical trials of new drugs.
Employing clinical trials of ‘epigenetic drugs’ for patients with blood cancers incorporating detailed laboratory studies on how these new drugs work and how to use them better.
In every cell there are chemical reactions that switch genes on and off; this gene control mechanism is called epigenetics and cancer can develop due to abnormal epigenetic reactions. There are exciting drugs in development that can target epigenetic changes to ‘re-programme’ the rogue cancer cell.
Membership is open to individuals who possess the qualifications and experience necessary to be a site or study investigator & support the aims of VEG. The scientific community benefits from the commitment and expertise of its members in delivering epigenetic translational research.